Publication - Report

Review of Access to New Medicines

Published: 14 Dec 2016

An independent review to assess the impact of the new approach introduced in 2014 by Scottish Medicines Consortium (SMC).

227 page PDF

5.7 MB

227 page PDF

5.7 MB

Contents
Review of Access to New Medicines
Appendix 2: Task & Finish Group Definitions for end-of-life, orphan and ultra-orphan medicines

227 page PDF

5.7 MB

Appendix 2: Task & Finish Group Definitions for end-of-life, orphan and ultra-orphan medicines

Task and Finish Group Definitions

End-of-Life Medicine:

"A medicine used to treat a condition at a stage that usually leads to death within 3 years with currently available treatments."

Orphan Medicine:

"A medicine with European Medicines Agency ( EMA) designated orphan status ( i.e. conditions affecting fewer than 2,500 people in a population of 5 million) or a medicine to treat an equivalent size of population irrespective of whether it has designated orphan status."

Ultra-Orphan Medicine:

"A medicine used to treat a condition with a prevalence of 1 in 50,000 or less (or around 100 people in Scotland)".


Contact